Biomarkers for trials of neuroprotection in Parkinson's disease
Identifieur interne : 000152 ( Istex/Corpus ); précédent : 000151; suivant : 000153Biomarkers for trials of neuroprotection in Parkinson's disease
Auteurs : Pankaj A. Agarwal ; A. Jon StoesslSource :
- Movement Disorders [ 0885-3185 ] ; 2013-01.
Abstract
With increased understanding of disease pathogenesis and the foreseeable reality of disease‐modifying therapies, there is a growing need to find biomarkers that will allow early (preferably preclinical) detection of disease and that will provide an independent readout of disease progression. In this article, we review a variety of markers, with a focus on functional imaging techniques, which while imperfect, currently provide the best approach to this problem. We consider the limitations of functional imaging of the dopamine system in assessing the progression of Parkinson's Disease (PD) as well as the potential use of structural imaging and emerging progress in other biochemical and molecular markers. While there is no single biomarker that will satisfy all requirements, some combination is likely to be of great use in identifying those subjects most likely to benefit from neuroprotective therapies, as well as in monitoring the effects of these interventions. © 2013 Movement Disorder Society
Url:
DOI: 10.1002/mds.25065
Links to Exploration step
ISTEX:07F59C467FC0683976CDE07244A017B4B0867BCDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biomarkers for trials of neuroprotection in Parkinson's disease</title><author><name sortKey="Agarwal, Pankaj A" sort="Agarwal, Pankaj A" uniqKey="Agarwal P" first="Pankaj A." last="Agarwal">Pankaj A. Agarwal</name><affiliation><mods:affiliation>Pacific Parkinson's Research Centre, University of British Columbia, British Columbia, Vancouver, Canada</mods:affiliation></affiliation></author><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name><affiliation><mods:affiliation>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Vancouver Costal Health, British Columbia, Vancouver, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: jstoessl@mail.ubc.ca</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:07F59C467FC0683976CDE07244A017B4B0867BCD</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1002/mds.25065</idno><idno type="url">https://api-v5.istex.fr/document/07F59C467FC0683976CDE07244A017B4B0867BCD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000152</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000152</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Biomarkers for trials of neuroprotection in Parkinson's disease</title><author><name sortKey="Agarwal, Pankaj A" sort="Agarwal, Pankaj A" uniqKey="Agarwal P" first="Pankaj A." last="Agarwal">Pankaj A. Agarwal</name><affiliation><mods:affiliation>Pacific Parkinson's Research Centre, University of British Columbia, British Columbia, Vancouver, Canada</mods:affiliation></affiliation></author><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name><affiliation><mods:affiliation>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Vancouver Costal Health, British Columbia, Vancouver, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: jstoessl@mail.ubc.ca</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov Disord</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-01">2013-01</date><biblScope unit="volume">28</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="71">71</biblScope><biblScope unit="page" to="85">85</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">07F59C467FC0683976CDE07244A017B4B0867BCD</idno><idno type="DOI">10.1002/mds.25065</idno><idno type="ArticleID">MDS25065</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">With increased understanding of disease pathogenesis and the foreseeable reality of disease‐modifying therapies, there is a growing need to find biomarkers that will allow early (preferably preclinical) detection of disease and that will provide an independent readout of disease progression. In this article, we review a variety of markers, with a focus on functional imaging techniques, which while imperfect, currently provide the best approach to this problem. We consider the limitations of functional imaging of the dopamine system in assessing the progression of Parkinson's Disease (PD) as well as the potential use of structural imaging and emerging progress in other biochemical and molecular markers. While there is no single biomarker that will satisfy all requirements, some combination is likely to be of great use in identifying those subjects most likely to benefit from neuroprotective therapies, as well as in monitoring the effects of these interventions. © 2013 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>dopaminergic</json:string><json:string>neurol</json:string><json:string>dopamine</json:string><json:string>striatal</json:string><json:string>biomarker</json:string><json:string>biomarkers</json:string><json:string>transporter</json:string><json:string>disord</json:string><json:string>parkinsonism</json:string><json:string>receptor</json:string><json:string>nigrostriatal</json:string><json:string>disease progression</json:string><json:string>tracer</json:string><json:string>imaging</json:string><json:string>spect</json:string><json:string>neurology</json:string><json:string>putamen</json:string><json:string>parkinson disease</json:string><json:string>substantia</json:string><json:string>striatum</json:string><json:string>vmat2</json:string><json:string>substantia nigra</json:string><json:string>nigral</json:string><json:string>mutation</json:string><json:string>nigra</json:string><json:string>pdrp</json:string><json:string>progression</json:string><json:string>neurodegenerative</json:string><json:string>lrrk2</json:string><json:string>dysfunction</json:string><json:string>parkinson</json:string><json:string>positron</json:string><json:string>movement disorders</json:string><json:string>radiotracer</json:string><json:string>presynaptic</json:string><json:string>idiopathic</json:string><json:string>monoamine</json:string><json:string>neurosci</json:string><json:string>preclinical</json:string><json:string>ndings</json:string><json:string>cerebrospinal</json:string><json:string>synaptic</json:string><json:string>oxidative</json:string><json:string>stoessl</json:string><json:string>dtbz</json:string><json:string>urate</json:string><json:string>early disease</json:string><json:string>tomography</json:string><json:string>schulzer</json:string><json:string>clinical trials</json:string><json:string>glucose</json:string><json:string>neuroimaging</json:string><json:string>proteomics</json:string><json:string>eckert</json:string><json:string>vesicle</json:string><json:string>levodopa</json:string><json:string>sossi</json:string><json:string>nucl</json:string><json:string>marek</json:string><json:string>behavior disorder</json:string><json:string>differential diagnosis</json:string><json:string>pdrp activity</json:string><json:string>neuron</json:string><json:string>pathogenesis</json:string><json:string>motor symptoms</json:string><json:string>striatal dopaminergic function</json:string><json:string>radiotracer imaging</json:string><json:string>arch neurol</json:string><json:string>healthy controls</json:string><json:string>compensatory changes</json:string><json:string>british columbia</json:string><json:string>positron emission tomography</json:string><json:string>sporadic disease</json:string><json:string>tracer uptake</json:string><json:string>tracer binding</json:string><json:string>striatal subregions</json:string><json:string>imaging techniques</json:string><json:string>glucose metabolism</json:string><json:string>functional imaging</json:string><json:string>clinical progression</json:string><json:string>diffusion tensor imaging</json:string><json:string>disease onset</json:string><json:string>recent study</json:string><json:string>cereb blood flow metab</json:string><json:string>other neurodegenerative disorders</json:string><json:string>vmat2 binding</json:string><json:string>ligand</json:string><json:string>marker</json:string><json:string>metabolism</json:string><json:string>potential biomarker</json:string><json:string>clinical improvement</json:string><json:string>neurol neurosurg psychiatry</json:string><json:string>network activity</json:string><json:string>dopaminergic dysfunction</json:string><json:string>psychogenic parkinsonism</json:string><json:string>network expression</json:string><json:string>essential tremor</json:string><json:string>white matter</json:string><json:string>transcranial ultrasound</json:string><json:string>functional neuroimaging</json:string><json:string>transcranial sonography</json:string><json:string>lancet neurol</json:string><json:string>dopamine transporter</json:string><json:string>dopaminergic function</json:string><json:string>oxidative stress</json:string><json:string>dopamine transporters</json:string><json:string>treatment group</json:string><json:string>other markers</json:string><json:string>synaptic vesicles</json:string><json:string>uptake</json:string><json:string>disorder</json:string><json:string>interrater consistency</json:string><json:string>pharmacological regulation</json:string><json:string>potential effects</json:string><json:string>disease process</json:string><json:string>clinical sign</json:string><json:string>functional radiotracer imaging</json:string><json:string>neurodegenerative diseases</json:string><json:string>lrrk2 mutations</json:string><json:string>lrrk2 mutation carriers</json:string><json:string>functional connectivity</json:string><json:string>high sensitivity</json:string><json:string>reliable biomarkers</json:string><json:string>functional imaging studies</json:string><json:string>placebo effects</json:string><json:string>other approaches</json:string><json:string>gene expression</json:string><json:string>healthy brain</json:string><json:string>plasma epidermal growth factor levels</json:string><json:string>cognitive impairment</json:string><json:string>accurate diagnosis</json:string><json:string>direct readout</json:string><json:string>iron deposition</json:string><json:string>further validation</json:string><json:string>laser mass spectrometry</json:string><json:string>compensatory upregulation</json:string><json:string>synaptic cleft</json:string><json:string>neurodegenerative disease</json:string><json:string>microstructural changes</json:string><json:string>several years</json:string><json:string>atypical parkinsonism</json:string><json:string>nigrostriatal dysfunction</json:string><json:string>neurosci lett</json:string><json:string>endogenous dopamine</json:string><json:string>energy metabolism</json:string><json:string>nigral cell counts</json:string><json:string>unilateral disease</json:string><json:string>spatial covariance pattern</json:string><json:string>single biomarker</json:string><json:string>preclinical duration</json:string><json:string>symptom onset</json:string><json:string>diagnostic accuracy</json:string><json:string>clinical data</json:string><json:string>older patients</json:string><json:string>human brain</json:string><json:string>imaging data</json:string><json:string>monoamine transporter</json:string><json:string>iron content</json:string><json:string>metabolic network activity</json:string><json:string>dopamine turnover</json:string><json:string>striatal dopamine</json:string><json:string>network modulation</json:string><json:string>nonlinear progression</json:string><json:string>striatonigral degeneration</json:string><json:string>positron emission tomography study</json:string><json:string>idiopathic disease</json:string><json:string>serum urate</json:string><json:string>slower rate</json:string><json:string>human cerebrospinal</json:string><json:string>posterior putamen</json:string></teeft></keywords><author><json:item><name>Pankaj A. Agarwal MD, DNB, DM</name><affiliations><json:string>Pacific Parkinson's Research Centre, University of British Columbia, British Columbia, Vancouver, Canada</json:string></affiliations></json:item><json:item><name>A. Jon Stoessl CM, MD, FRCPC</name><affiliations><json:string>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia, Canada</json:string><json:string>Vancouver Costal Health, British Columbia, Vancouver, Canada</json:string><json:string>E-mail: jstoessl@mail.ubc.ca</json:string></affiliations></json:item></author><articleId><json:string>MDS25065</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>With increased understanding of disease pathogenesis and the foreseeable reality of disease‐modifying therapies, there is a growing need to find biomarkers that will allow early (preferably preclinical) detection of disease and that will provide an independent readout of disease progression. In this article, we review a variety of markers, with a focus on functional imaging techniques, which while imperfect, currently provide the best approach to this problem. We consider the limitations of functional imaging of the dopamine system in assessing the progression of Parkinson's Disease (PD) as well as the potential use of structural imaging and emerging progress in other biochemical and molecular markers. While there is no single biomarker that will satisfy all requirements, some combination is likely to be of great use in identifying those subjects most likely to benefit from neuroprotective therapies, as well as in monitoring the effects of these interventions. © 2013 Movement Disorder Society</abstract><qualityIndicators><score>6.8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 809.972 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1007</abstractCharCount><pdfWordCount>10687</pdfWordCount><pdfCharCount>71815</pdfCharCount><pdfPageCount>15</pdfPageCount><abstractWordCount>150</abstractWordCount></qualityIndicators><title>Biomarkers for trials of neuroprotection in Parkinson's disease</title><genre><json:string>review-article</json:string></genre><host><title>Movement Disorders</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi><issn><json:string>0885-3185</json:string></issn><eissn><json:string>1531-8257</json:string></eissn><publisherId><json:string>MDS</json:string></publisherId><volume>28</volume><issue>1</issue><pages><first>71</first><last>85</last><total>15</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Review</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>2013</publicationDate><copyrightDate>2013</copyrightDate><doi><json:string>10.1002/mds.25065</json:string></doi><id>07F59C467FC0683976CDE07244A017B4B0867BCD</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/07F59C467FC0683976CDE07244A017B4B0867BCD/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/07F59C467FC0683976CDE07244A017B4B0867BCD/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/07F59C467FC0683976CDE07244A017B4B0867BCD/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Biomarkers for trials of neuroprotection in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><availability><p>Copyright © 2013 Movement Disorder SocietyCopyright © 2013 Movement Disorders Society</p></availability><date>2013-02-06</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Biomarkers for trials of neuroprotection in Parkinson's disease</title><author xml:id="author-1"><persName><forename type="first">Pankaj A.</forename><surname>Agarwal</surname></persName><roleName type="degree">MD, DNB, DM</roleName><affiliation>Pacific Parkinson's Research Centre, University of British Columbia, British Columbia, Vancouver, Canada</affiliation></author><author xml:id="author-2"><persName><forename type="first">A. Jon</forename><surname>Stoessl</surname></persName><roleName type="degree">CM, MD, FRCPC</roleName><email>jstoessl@mail.ubc.ca</email><affiliation>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia, Canada</affiliation><affiliation>Vancouver Costal Health, British Columbia, Vancouver, Canada</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov Disord</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-01"></date><biblScope unit="volume">28</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="71">71</biblScope><biblScope unit="page" to="85">85</biblScope></imprint></monogr><idno type="istex">07F59C467FC0683976CDE07244A017B4B0867BCD</idno><idno type="DOI">10.1002/mds.25065</idno><idno type="ArticleID">MDS25065</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2013-02-06</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>With increased understanding of disease pathogenesis and the foreseeable reality of disease‐modifying therapies, there is a growing need to find biomarkers that will allow early (preferably preclinical) detection of disease and that will provide an independent readout of disease progression. In this article, we review a variety of markers, with a focus on functional imaging techniques, which while imperfect, currently provide the best approach to this problem. We consider the limitations of functional imaging of the dopamine system in assessing the progression of Parkinson's Disease (PD) as well as the potential use of structural imaging and emerging progress in other biochemical and molecular markers. While there is no single biomarker that will satisfy all requirements, some combination is likely to be of great use in identifying those subjects most likely to benefit from neuroprotective therapies, as well as in monitoring the effects of these interventions. © 2013 Movement Disorder Society</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2012-01-18">Received</change><change when="2012-04-23">Registration</change><change when="2013-02-06">Created</change><change when="2013-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/07F59C467FC0683976CDE07244A017B4B0867BCD/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en" xml:id="mds25065"><header><publicationMeta level="product"><doi origin="wiley" registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov Disord</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi>10.1002/mds.v28.1</doi><titleGroup><title type="specialIssueTitle">The Vatican Conference on Neuroprotection in Parkinson's Disease</title></titleGroup><copyright ownership="publisher">Copyright © 2013 Movement Disorder Society</copyright><numberingGroup><numbering type="journalVolume" number="28">28</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2013-01">January 2013</coverDate></publicationMeta><publicationMeta level="unit" position="100" type="reviewArticle" status="forIssue"><doi>10.1002/mds.25065</doi><idGroup><id type="unit" value="MDS25065"></id></idGroup><countGroup><count type="pageTotal" number="15"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="publisher">Copyright © 2013 Movement Disorders Society</copyright><eventGroup><event type="manuscriptReceived" date="2012-01-18"></event><event type="manuscriptRevised" date="2012-04-19"></event><event type="manuscriptAccepted" date="2012-04-23"></event><event type="xmlCreated" agent="Cenveo Publisher Services" date="2013-02-06"></event><event type="publishedOnlineEarlyUnpaginated" date="2012-08-24"></event><event type="firstOnline" date="2012-08-24"></event><event type="publishedOnlineFinalForm" date="2013-02-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.6.4 mode:FullText" date="2015-10-03"></event></eventGroup><numberingGroup><numbering type="pageFirst">71</numbering><numbering type="pageLast">85</numbering></numberingGroup><correspondenceTo><b>Correspondence to:</b> A. Jon Stoessl, Pacific Parkinson's Research Center, University of British Columbia, Vancouver Hospital and Health Sciences Center, Purdy Pavilion, 2221Wesbrook Mall, Vancouver, British Columbia, Canada V6T 2B5; <email>jstoessl@mail.ubc.ca</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS25065.pdf"></link></linkGroup></publicationMeta><contentMeta><titleGroup><title type="main">Biomarkers for trials of neuroprotection in Parkinson's disease</title><title type="short">Biomarkers of Neuroprotection in PD</title></titleGroup><creators><creator affiliationRef="#mds25065-aff-0001" creatorRole="author" xml:id="mds25065-cr-0001"><personName><givenNames>Pankaj A.</givenNames><familyName>Agarwal</familyName><degrees>MD, DNB, DM</degrees></personName></creator><creator affiliationRef="#mds25065-aff-0001 #mds25065-aff-0002" corresponding="yes" creatorRole="author" xml:id="mds25065-cr-0002"><personName><givenNames>A. Jon</givenNames><familyName>Stoessl</familyName><degrees>CM, MD, FRCPC</degrees></personName></creator></creators><affiliationGroup><affiliation type="organization" xml:id="mds25065-aff-0001" countryCode="CA"><orgDiv>Pacific Parkinson's Research Centre</orgDiv><orgName>University of British Columbia</orgName><address><city>Vancouver</city><countryPart>British Columbia</countryPart><country>Canada</country></address></affiliation><affiliation type="organization" xml:id="mds25065-aff-0002" countryCode="CA"><orgName>Vancouver Costal Health</orgName><address><city>Vancouver</city><countryPart>British Columbia</countryPart><country>Canada</country></address></affiliation></affiliationGroup><abstractGroup><abstract type="main"><p>With increased understanding of disease pathogenesis and the foreseeable reality of disease‐modifying therapies, there is a growing need to find biomarkers that will allow early (preferably preclinical) detection of disease and that will provide an independent readout of disease progression. In this article, we review a variety of markers, with a focus on functional imaging techniques, which while imperfect, currently provide the best approach to this problem. We consider the limitations of functional imaging of the dopamine system in assessing the progression of Parkinson's Disease (PD) as well as the potential use of structural imaging and emerging progress in other biochemical and molecular markers. While there is no single biomarker that will satisfy all requirements, some combination is likely to be of great use in identifying those subjects most likely to benefit from neuroprotective therapies, as well as in monitoring the effects of these interventions. © 2013 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="mds25065-note-0001"><p><b>Funding agencies</b>: The work of A.J.S. is supported by the Canadian Institutes of Health Research, the Michael J. Fox Foundation, the Pacific Alzheimer Research Foundation, and the Canada Research Chairs program.</p></note><note xml:id="mds25065-note-0002"><p><b>Relevant conflicts of interest/financial disclosure</b>: Nothing to report.</p></note><note xml:id="mds25065-note-0003"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Biomarkers for trials of neuroprotection in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Biomarkers of Neuroprotection in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Biomarkers for trials of neuroprotection in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Pankaj A.</namePart><namePart type="family">Agarwal</namePart><namePart type="termsOfAddress">MD, DNB, DM</namePart><affiliation>Pacific Parkinson's Research Centre, University of British Columbia, British Columbia, Vancouver, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A. Jon</namePart><namePart type="family">Stoessl</namePart><namePart type="termsOfAddress">CM, MD, FRCPC</namePart><affiliation>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia, Canada</affiliation><affiliation>Vancouver Costal Health, British Columbia, Vancouver, Canada</affiliation><affiliation>E-mail: jstoessl@mail.ubc.ca</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><dateIssued encoding="w3cdtf">2013-01</dateIssued><dateCreated encoding="w3cdtf">2013-02-06</dateCreated><dateCaptured encoding="w3cdtf">2012-01-18</dateCaptured><dateValid encoding="w3cdtf">2012-04-23</dateValid><copyrightDate encoding="w3cdtf">2013</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>With increased understanding of disease pathogenesis and the foreseeable reality of disease‐modifying therapies, there is a growing need to find biomarkers that will allow early (preferably preclinical) detection of disease and that will provide an independent readout of disease progression. In this article, we review a variety of markers, with a focus on functional imaging techniques, which while imperfect, currently provide the best approach to this problem. We consider the limitations of functional imaging of the dopamine system in assessing the progression of Parkinson's Disease (PD) as well as the potential use of structural imaging and emerging progress in other biochemical and molecular markers. While there is no single biomarker that will satisfy all requirements, some combination is likely to be of great use in identifying those subjects most likely to benefit from neuroprotective therapies, as well as in monitoring the effects of these interventions. © 2013 Movement Disorder Society</abstract><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov Disord</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Review</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2013</date><detail type="title"><title>The Vatican Conference on Neuroprotection in Parkinson's Disease</title></detail><detail type="volume"><caption>vol.</caption><number>28</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>71</start><end>85</end><total>15</total></extent></part></relatedItem><identifier type="istex">07F59C467FC0683976CDE07244A017B4B0867BCD</identifier><identifier type="DOI">10.1002/mds.25065</identifier><identifier type="ArticleID">MDS25065</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2013 Movement Disorder SocietyCopyright © 2013 Movement Disorders Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000152 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000152 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:07F59C467FC0683976CDE07244A017B4B0867BCD
|texte= Biomarkers for trials of neuroprotection in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |